FIRECREST Customer Support

Steatotic (fatty) liver disease is a silent global epidemic, often underdiagnosed despite its growing impact. Beyond the liver, it is closely linked to obesity, type 2 diabetes andhyperlipidaemia, driving significant car...

We're proud to share that ICON has been named one of Forbes America's Best Employers for New Graduates 2026. The recognition is based on independent surveys of early-career professionals across the US, covering culture,...

We are excited to announce that Cytek Aurora 5L Spectral Flow Cytometers are now live in our bioanalytical labs in the Netherlands and US. With the new addition we are offering: 1) Development/transfer, validation, and ...

Site performance remains one of the most critical drivers of trial success. Through FIRECREST, ICON is enhancing site engagement, improving consistency and delivering stronger study execution at scale. Visit Booth \#1426...

Cut point determination is essential in ADA assay development, and while statistical methods like Tukey’s test can lead to ultra-low cut points (ULCPs), concerns around reliability and false positives may be overstated. ...

ICON is proud to sponsor the SOLAR conference. Our hepatology specialists will be on-site (25-27 June), talking with peers about the practical side of running liver disease trials from AI-driven site selection to imagi...

Last week, we proudly celebrated a significant milestone, 30 years of ICON Germany. Over the past three decades, our teams in Germany have played an important role in advancing clinical research and supporting customer...

Meet the ICON team at #OCTUK26 tomorrow. Our team is gearing up for industry updates and dynamic discussions on how we can help drive success for your clinical trial. Visit us at booth \#42 to explore our expertise spa...

In global obesity trials, DXA is valued for fast, patient-friendly assessment of body composition and visceral fat. However, standard DXA field-of-view can miss full abdominal capture in larger body sizes, leading to “si...

Celebrating 20 years of ICON in Poland. Since our Polish branch was established in Warsaw in 2006, ICON Poland has grown into a team of more than 1,800 employees across Warsaw, Gdańsk, and remote working locations. Ove...

ICON Biotech is sponsoring #OCTUK26, taking place 9–10 June in London. Visit us at booth \#42 to learn how we’re advancing clinical trial solutions through innovation, operational excellence and deep therapeutic experti...

Biologic viral safety is entering a new phase. Updated global ICH guidance is reshaping how manufacturers approach risk based controls, modern analytics and manufacturing innovation. In this PharmTech feature, John M. e...